Common genetic alterations, including FOXA1 mutations, gain of the androgen receptor gene (AR amplification or mutation), and structural variants such as loss of NKX3.1 (8p21) and PTEN (10q23), account for prostate carcinogenesis. This evidence concerns the gene PTEN and urogenital neoplasm.